Chronic Obstructive Pulmonary Disease
Conditions
Keywords
COPD
Brief summary
Trial to evaluate the dose response of SCH 527123 in reducing inflammation from an ozone-induced sputum neutrophilia in both healthy subjects and subjects with COPD.
Interventions
DRUGSCH 527123
Very low dose SCH 527123, once daily for 7 days
DRUGPlacebo
Placebo capsules to match SCH 527123, once daily for 7 days
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Part 1 * Subject of either sex and of any race between the age of 18 and 55 years, with a BMI (weight \[kg\]/height \[m2\]) between 19 and 32. * Subject must have a FEV1 ≥ 80 % of predicted value. * Subject must be nonsmoker (including cigarettes, cigars and pipes) or exsmoker who has stopped smoking for at least 6 months (smoking history ≤ 5 pack years). * Subject's clinical laboratory tests (CBC, blood chemistry, urinalysis) must be within normal limits. Subjects must have a neutrophil count of \>2.0 x 109/L. (also Part 2) * Subject must be free of any clinically significant disease that would interfere with the study evaluations (also Part 2). * Screening ECG conduction intervals must be within gender specific normal range; QTcB males ≤430 msec and females ≤450 msec (also Part 2). * Vital sign measurements must be: a) oral body temperature, between 35.0°C and 37.5°C; b) systolic blood pressure, 90 to 140 mm Hg (160 mm Hg, Part 2); c) diastolic blood pressure, 45 to 90 mm Hg (100 mm Hg, Part 2); d) pulse rate, 40 to 100 bpm. * Subject and partner(s) must be using an accepted method of contraception during the trial through 2 months post-treatment (also Part 2). * Prior to randomization, subject must be a responder to ozone (also Part 2). Part 2 * Subject with a diagnosis of COPD for at least 1 year and FEV1 ≥65% of predicted value post bronchodilation (measurement 30 minutes after 400 mcg salbutamol administration) and FEV1/FVC of \<70%. * Subject of either sex and of any race between the age of 40 and 65 years, with a BMI between 19 and 32. * Subject must be active or exsmoker (cigarettes, cigars and/or pipes). * Subject must have a normal exercise stress test (no clinically significant ECG findings).
Exclusion criteria
Part 1 and Part 2 * Female subject who is pregnant, intends to become pregnant (within 3 months of ending the study), or is breastfeeding. * Subject with history of seasonal or perennial allergic rhinitis (ie, season for specific allergen). * Subject who has an allergy or a contraindication to excipients in placebo or SCH 527123 formulations or salbutamol. * Surgical or medical condition (history or presence) which might alter the ADME of the drug: a) inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding; b) major gastrointestinal tract surgery, ie, gastrectomy, gastroenterostomy, or bowel resection; c) pancreatic injury or pancreatitis; d) liver disease or injury; e) impaired renal function indicated by abnormal creatinine, urinary albumin, BUN/urea or clinical significant urinary cellular constituents (eg, cast); or f) urinary obstruction or difficulty in voiding. * Subject who has any infectious disease within 4 weeks prior to drug administration. * Subject who is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV. * Subject who has a positive screen for drugs with a high potential for abuse (Screening and/or treatment period). * Subjects with a history of mental instability or who have been treated for mood disorder. * Subject with a history of alcohol or drug abuse in the past 2 years. * Subject who has donated blood in the past 60 days. * Subject who has demonstrated allergic reactions (eg, food, drug, atopic reactions or asthmatic episodes) which may interfere with ability to participate in the trial. * Subject who has previously received SCH 527123 (Part 2 only) * Subject who has received any of the following treatments more recently than indicated washout period prior to Baseline: * Parts 1 and 2: OTC medications (excluding paracetamol), 14 days. * Part 1: prescription medications, 14 days; investigational drugs, 30 days. * Part 2: vitamins and herbal supplements, 14 days; statins, 4 weeks; steroids (inhaled), 4 weeks; steroids (oral and dermal), 8 weeks; antibiotics, 6 weeks; leukotriene antagonists, 4 weeks; NSAIDS, 2 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PD/PK: Dose response of SCH 527123 on ozone-induced sputum neutrophilia in healthy subjects (Part 1) and subjects with COPD (Part 2), measured by placebo-adjusted percent change in sputum neutrophil counts and absolute sputum neutrophil counts. | Part 1, four treatment periods, Part 2 three treatment periods duration of the trial. |
Outcome results
None listed